Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.
Eli Lilly and Company (NYSE: LLY) generates frequent news across cardiometabolic health, oncology, immunology, obesity and manufacturing expansion. This page aggregates recent press releases and third-party coverage so readers can follow how Lilly’s medicines, clinical programs and corporate actions are evolving over time.
Recent updates show Lilly reporting Phase 3 results for multiple late-stage assets. In obesity and cardiometabolic health, the company has shared topline data from ATTAIN-MAINTAIN, a Phase 3 trial of orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for weight maintenance after prior treatment with injectable incretin therapies. Lilly has also reported results from TRIUMPH-4, a Phase 3 trial of retatrutide, an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight and knee osteoarthritis, with co-primary endpoints in weight loss and pain reduction.
In immunology, Lilly has announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. The company reports that the combination met the primary endpoint and all key secondary endpoints, supporting an integrated approach to treating psoriatic arthritis and obesity.
Oncology news includes updated EMBER-3 data for Inluriyo (imlunestrant) as monotherapy and in combination with Verzenio (abemaciclib) in ER-positive, HER2-negative advanced breast cancer, and Phase 3 BRUIN CLL-313 results showing that Jaypirca (pirtobrutinib) significantly reduced the risk of progression or death versus chemoimmunotherapy in treatment-naïve CLL/SLL without 17p deletions.
Corporate and strategic news items cover Lilly’s planned acquisition of Ventyx Biosciences, completion of the Adverum Biotechnologies tender offer, a strategic collaboration with Aktis Oncology, and a major manufacturing investment in a new active pharmaceutical ingredient facility in Huntsville, Alabama. Investors and observers can use this news feed to monitor clinical milestones, regulatory submissions, acquisitions, collaborations, financing activities and manufacturing expansions related to LLY.
Eli Lilly has pledged $5 million over five years to support Direct Relief's Fund for Health Equity, which aims to enhance healthcare access in underserved communities. This commitment is part of Lilly's broader Racial Justice Initiative, addressing systemic health inequities affecting minority groups. Direct Relief focuses on strengthening health organizations through grants that improve leadership, preventive strategies, chronic disease management, and access to innovative technologies.
Eli Lilly reported Q1 2021 financial results with revenue of $6.806 billion, a 16% increase from Q1 2020. Net income decreased 7% to $1.355 billion, with a reported EPS of $1.49. Non-GAAP net income rose 16% to $1.702 billion, with an EPS of $1.87. Key growth products contributed 46% of total revenue, driven by strong sales in diabetes and cancer treatment. Lilly's COVID-19 antibodies generated $810.1 million in revenue. Despite increased R&D expenses by 21%, Lilly gained significant advancements in clinical trials for several promising therapies.
Eli Lilly's Taltz (ixekizumab) has shown superior treatment outcomes for adults with moderate to severe plaque psoriasis compared to seven other biologics, according to a recent analysis. This network meta-analysis revealed that Taltz provided patients with an average of 159 days of completely clear skin in one year. Additionally, Taltz users demonstrated better medication adherence and persistence, staying on treatment approximately 22 weeks longer than those using other biologics. The findings were presented at the American Academy of Dermatology's Virtual Meeting, highlighting Taltz's role in enhancing patient quality of life.
Recent analyses from the BREEZE-AD5 Phase 3 clinical trial reveal that Eli Lilly and Incyte's OLUMIANT (baricitinib) 2-mg tablet significantly improves treatment outcomes for adults with moderate to severe atopic dermatitis (AD). The data shows remarkable early improvements in symptom severity and quality of life, with over 50% improvement in Eczema Area and Severity Index (EASI) scores at four weeks. An extended safety analysis across eight studies indicates no increased risk of serious adverse events. Results were presented at the AAD Virtual Meeting from April 23-25, 2021.
Eli Lilly and Incyte announced successful results from the Phase 3 trials BRAVE-AA1 and BRAVE-AA2, evaluating baricitinib for severe alopecia areata. Both trials showed significant hair regrowth improvement in patients treated with 2-mg and 4-mg doses compared to placebo.
At Week 36, 35% of patients on 4-mg achieved at least 80% scalp hair coverage, while 22% on 2-mg did the same, leading to plans for a supplemental New Drug Application to the FDA in late 2021. Baricitinib, already approved for RA, may become the first approved treatment for this autoimmune disease.
Eli Lilly has requested the FDA to revoke the Emergency Use Authorization for bamlanivimab (LY-CoV555) alone due to the emergence of COVID-19 variants and the full availability of bamlanivimab combined with etesevimab. This decision is part of a strategy to transition to administering both monoclonal antibodies together, which offer better neutralization against variants. More than 400,000 patients have been treated with bamlanivimab, avoiding significant hospitalizations and fatalities during the pandemic. Lilly aims to complete this transition by June 2021.
Eli Lilly and Company (NYSE: LLY) announced the appointment of Diogo Rau as the new senior vice-president and chief information and digital officer, effective May 17, 2021. Rau takes over from Aarti Shah, who is retiring after 27 years at Lilly. With a strong background at Apple and McKinsey, Rau is expected to enhance Lilly’s digital capabilities, focusing on data, analytics, and machine learning to improve patient experiences. CEO David A. Ricks praised Rau’s leadership potential in revolutionizing their technology strategy.
Eli Lilly and Company (NYSE: LLY) announced key changes to its purchase agreements with the U.S. government for COVID-19 treatments. The company will focus on supplying bamlanivimab and etesevimab together, terminating the agreement for bamlanivimab alone. This includes canceling 350,856 doses of bamlanivimab previously scheduled for delivery by March 2021. Both treatments remain authorized under Emergency Use Authorization, but their efficacy and safety in COVID-19 management continue to be evaluated.
Eli Lilly (NYSE: LLY) has unveiled promising Phase 1/2 LIBRETTO-001 trial data for Retevmo (selpercatinib), showing significant antitumor activity against RET fusion-positive advanced solid tumors beyond lung and thyroid cancers, especially in challenging gastrointestinal malignancies. Presenting at the AACR Annual Meeting 2021, the trial involved 32 patients, revealing a 47% objective response rate with 73% of responders maintaining ongoing results. Safety profiles aligned with prior data, with no treatment discontinuations due to adverse events. Lilly aims to discuss these findings with regulatory authorities.
Eli Lilly and Incyte reported on April 8, 2021, that the COV-BARRIER Phase 3 trial of baricitinib did not meet its primary endpoint of reducing mechanical ventilation or death by Day 28. Baricitinib showed a 2.7% lesser progression risk compared to placebo, which was not statistically significant. However, a significant 38% reduction in all-cause mortality was noted among baricitinib patients. The trial included 1,525 participants across various countries. Lilly plans to publish detailed findings and share them with regulatory authorities for further validation of baricitinib's efficacy in treating COVID-19.